EI
AKRO

EAM Investors’s Akero Therapeutics AKRO Stock Holding History

EAM Investors’s Portfolio AKRO Stock Details AKRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-66,422
Closed -$2.69M – 227
2025
Q1 		$2.69M Buy
+66,422
New +$2.82M 0.46% 112
2023
Q3 		– Sell
-50,856
Closed -$2.37M – 277
2023
Q2 		$2.37M Buy
50,856
+6,169
+14% +$283K 0.44% 86
2023
Q1 		$1.71M Sell
44,687
-8,825
-16% -$393K 0.34% 142
2022
Q4 		$2.93M Sell
53,512
-31,095
-37% -$1.33M 0.61% 41
2022
Q3 		$2.88M Buy
+84,607
New +$1.29M 0.63% 37
2020
Q4 		– Sell
-63,928
Closed -$1.97M – 295
2020
Q3 		$1.97M Buy
+63,928
New +$2.23M 0.47% 60

Other funds holding AKRO

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GA
General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

EAM Investors's AKRO Position: Q2 2025 in Review

EAM Investors sold out of Akero Therapeutics (AKRO) in Q2 2025, closing a stake of 66,422 shares — an estimated $2.69M sold.

EAM Investors first reported a position in AKRO in Q3 2020 and held it in 6 quarters. The position peaked at $2.93M in Q4 2022. 257 funds tracked by Wall St. Rank hold AKRO as of Q2 2025.

  • EAM Investors reported no remaining Akero Therapeutics position as of Q2 2025 after selling out during the quarter.
  • EAM Investors sold 66,422 Akero Therapeutics shares in Q2 2025, an estimated $2.69M.
  • EAM Investors first reported a position in Akero Therapeutics in Q3 2020 and held it in 6 quarters.
  • EAM Investors's Akero Therapeutics position peaked at $2.93M in Q4 2022.
  • 257 funds tracked by Wall St. Rank held Akero Therapeutics as of Q2 2025.

Based on EAM Investors's 13F filing for Q2 2025, filed 12 Aug 2025.